Wave strengthens case for accelerated approval, with more positive Duchenne data

Ayisha Sharma

News Reporter

Wave Life Sciences shared updated results from a Phase 2 trial of its exon-skipping oligonucleotide candidate in Duchenne muscular dystrophy, bolstering its plans to file …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Wave strengthens case for accelerated approval, with more positive Duchenne data

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

Small biotech joins list of health companies taking a trip to Trump's Mar-a-Lago

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

FDA approves Sanofi's RNAi drug for hemophilia A and B

Wave strength­ens case for ac­cel­er­at­ed ap­proval, with more pos­i­tive Duchenne da­ta

News Reporter

Sign up to read this article for free.

more like this

Gondolabio

Palo Alto, CA, USA

Wave strengthens case for accelerated approval, with more positive Duchenne data